ArticleMethods in molecular biology (Clifton, N.J.)2026
Mouse Models of Platelet Alloimmunization and Refractoriness.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have established murine models of platelet alloimmunization and refractoriness. Our approaches utilize commonly available strains of mice, along with flow cytometry-based techniques to evaluate the magnitude and quality of the alloimmune response to platelet transfusion and the functional outcomes of these alloresponses. Using these methods, we can evaluate the relative immunogenicity of different blood products, the impact of recipient health on alloimmunization outcomes, and the ability of different interventions to prevent these damaging responses. Here, we discuss the approaches used to prepare platelets for transfusion, measure anti-class I and class II major histocompatibility complex (MHC) alloantibody responses, and assess the ability of these antibodies to mediate platelet refractoriness.
Indexed as
Identifiers
42681406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.